MARKSANS PHARMA LTD.

Company Profile

MARKSANS PHARMA LTD. had its IPO on under the ticker symbol MARKSANS.

The company operates in the Healthcare sector and Drug Manufacturers-General industry. MARKSANS PHARMA LTD. has a staff strength of 0 employees.

Stock update

Shares of MARKSANS PHARMA LTD. opened at ₹109 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹102.65 - ₹109, and closed at ₹105.9.

This is a -0.09% slip from the previous day's closing price.

A total volume of 447,354 shares were traded at the close of the day’s session.

In the last one week, shares of MARKSANS PHARMA LTD. have slipped by -3.86%.

MARKSANS PHARMA LTD.'s Key Ratios

MARKSANS PHARMA LTD. has a market cap of ₹49.53 billion, indicating a price to book ratio of 2.0198 and a price to sales ratio of 1.5594.

In the last 12-months MARKSANS PHARMA LTD.’s revenue was ₹18.52 billion with a gross profit of ₹9.31 billion and an EBITDA of ₹3.39 billion. The EBITDA ratio measures MARKSANS PHARMA LTD.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, MARKSANS PHARMA LTD.’s operating margin was 15.52% while its return on assets stood at 9.38% with a return of equity of 17.76%.

In Q1, MARKSANS PHARMA LTD.’s quarterly earnings growth was a positive 167% while revenue growth was a positive 16.2%.

MARKSANS PHARMA LTD.’s PE and PEG Ratio

Forward PE

0

Trailing PE

17.0515

PEG

Its diluted EPS in the last 12-months stands at ₹6.41 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into MARKSANS PHARMA LTD.’s profitability.

MARKSANS PHARMA LTD. stock is trading at a EV to sales ratio of 1.3954 and a EV to EBITDA ratio of 7.0126. Its price to sales ratio in the trailing 12-months stood at 1.5594.

MARKSANS PHARMA LTD. stock pays annual dividends of ₹0.5 per share, indicating a yield of 0.47% and a payout ratio of 16.49%.

Balance sheet and cash flow metrics

Total Assets

₹21.90 billion

Total Liabilities

₹3.41 billion

Operating Cash Flow

₹-2592120000.00

Capital Expenditure

₹536.31 million

Dividend Payout Ratio

16.49%

MARKSANS PHARMA LTD. ended 2024 with ₹21.90 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹21.90 billion while shareholder equity stood at ₹17.45 billion.

MARKSANS PHARMA LTD. ended 2024 with ₹0 in deferred long-term liabilities, ₹3.41 billion in other current liabilities, 453160000.00 in common stock, ₹17.00 billion in retained earnings and ₹384.89 million in goodwill. Its cash balance stood at ₹3.82 billion and cash and short-term investments were ₹7.19 billion. The company’s total short-term debt was ₹415,880,000 while long-term debt stood at ₹0.

MARKSANS PHARMA LTD.’s total current assets stands at ₹16.75 billion while long-term investments were ₹0 and short-term investments were ₹41.95 million. Its net receivables were ₹4.17 billion compared to accounts payable of ₹2.31 billion and inventory worth ₹4.85 billion.

In 2024, MARKSANS PHARMA LTD.'s operating cash flow was ₹-2592120000.00 while its capital expenditure stood at ₹536.31 million.

Comparatively, MARKSANS PHARMA LTD. paid ₹0.16 in dividends in 2024.

Other key metrics

Current Trading Price

₹105.9

52-Week High

₹113.39

52-Week Low

₹45.395

Analyst Target Price

₹

MARKSANS PHARMA LTD. stock is currently trading at ₹105.9 per share. It touched a 52-week high of ₹113.39 and a 52-week low of ₹113.39. Analysts tracking the stock have a 12-month average target price of ₹.

Its 50-day moving average was ₹109.12 and 200-day moving average was ₹80.5 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 4399.3% of the company’s stock are held by insiders while 1359.5% are held by institutions.